Idecabtagene Vicleucel (ide-cel, bb2121), A BCMA-Directed Car T cell therapy, in patients with Relapsed and Refractory Multiple Myeloma (RRMM): Initial Kar... Ide-cel, a BCMA targeted CAR T cell therapy, showed promising tolerability and efficacy in RRMM pts in the phase I CRB-401 ...
"bb21217 drug product is enriched for memory-like T cells, which are associated with robust CAR T cell expansion and less disease progression at month 6," said Berdeja. “Long-term CAR T-cell persistence was observed in 8 of 10 evaluable patients at month 6 and 2 of 2 at month 18....
Clinical remissions and limited toxicity in a first-in -human multicenter study of bb2121, a novel anti -BCMA CAR T cell therapy for relapsed / refractory multiple myeloma[J]. Eur J Cancer,2016,69(Suppl 1):S5. doi:10.1016/ S0959-8049(16)32614-4....
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA
Persistence of CAR T cells post infusion may be one determinant of duration of response. bb21217 is a next-generation anti-BCMA CAR T cell therapy based on investigational therapy idecabtagene vicleucel (bb2121) (Friedman 2018, Hum Gene Ther 29:585) that uses the same lentiviral CAR T ...
and refractory multiple myeloma to participate in a Phase II clinical trial (KarMMa) for efficacy and safety study of the CAR T-cell therapy bb2121. ... ZJ Ou - 《Value in Health》 被引量: 0发表: 2019年 Effects of oxidation on copper-binding properties of A1-16 peptide: a pulse radi...
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, demonstrated promising efficacy in triple-class exposed and highly refractory patients with multiple myeloma in the pivotal phase 2 KarMMa study, with an overall response rate (ORR), complete response (CR) rate, ...
223 - Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Subanalysis of the KarMMa Trialdoi:10.1016/S2666-6367(22)00384-0Nina Shah...
bb21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as idecabtagene vicleucel (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP) for memory-like T cells, thereby reducing the proportion of highly differentiated or...